These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32837113)

  • 21. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
    Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
    Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library.
    Shahhamzehei N; Abdelfatah S; Efferth T
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual targeting of 3CL
    Rajpoot S; Alagumuthu M; Baig MS
    Curr Res Struct Biol; 2021; 3():9-18. PubMed ID: 33319212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.
    Jukič M; Kores K; Janežič D; Bren U
    Front Chem; 2021; 9():757826. PubMed ID: 35028304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
    Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
    Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
    Bepari AK; Reza HM
    PeerJ; 2021; 9():e11261. PubMed ID: 33954055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
    Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
    Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.